Why Avoid Live Vaccines with Cosentyx?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune responses. Live vaccines contain weakened live viruses or bacteria that replicate in the body to build immunity. Combining them risks uncontrolled replication of the vaccine virus, leading to severe infections.[1][2]
Specific Risks
- Disseminated Infections: The vaccine pathogen can spread beyond the injection site, causing widespread illness. Examples include varicella-zoster (chickenpox/shingles vaccine), measles-mumps-rubella (MMR), oral polio, yellow fever, and live typhoid vaccines.[1]
- Reactivation of Latent Viruses: Cosentyx may worsen outcomes from vaccines like shingles, potentially leading to herpes zoster dissemination.[2]
- No Data on Safety: Clinical trials excluded live vaccines, so effects are unknown but presumed risky based on IL-17's role in fighting intracellular pathogens.[1][3]
Official Recommendations
Novartis and regulators advise:
- Avoid live vaccines during Cosentyx treatment.
- Complete all live vaccines at least 4 weeks before starting Cosentyx.
- For unavoidable cases (e.g., travel), assess risks with a doctor; inactivated vaccines (e.g., flu shot, Tdap) are safe and recommended.[1][2]
| Vaccine Type | Examples | Safe with Cosentyx? |
|--------------|----------|---------------------|
| Live/Attenuated | MMR, Varicella, Oral Typhoid, Yellow Fever | No |
| Inactivated | IPV, Inactivated Flu, Hepatitis A/B, HPV | Yes[1] |
What If You've Already Had a Live Vaccine?
Consult a doctor immediately. Monitor for infection signs like fever, rash, or unusual fatigue. Discontinue Cosentyx if vaccine-related illness occurs.[2]
Impact on Vaccination Schedules
Patients on Cosentyx should update records and prioritize non-live options. Household contacts can receive live vaccines, but avoid sharing bodily fluids or aerosols during the peak response period.[1]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: European Medicines Agency (EMA) Summary of Product Characteristics